Grants Awarded for Study of Changing US Health-Care Market Force
December 1st 1995WASHINGTON--The Agency for Health Care Policy and Research (AHCPR) has awarded 10 research grants to study changes that are reshaping America's health-care system (see list below). The grants total $1.4 million for the first year; most of the projects will be completed in 2 years or less.
Cancer Initiative Seeks Better Health Outcomes Via Counseling
December 1st 1995WASHINGTON--The Center for the Advancement of Health is working on a 3-year cancer initiative whose purpose is to increase support for psycho-social and biobehavioral research and services for cancer patients, said executive director Jessie Gruman, PhD. The Center was founded in 1992 by the John D. and Catherine T. MacArthur Foundation and the Nathan Cummings Foundation.
Men Have Higher Lifetime Ca Risk Than Women: SEER Data
December 1st 1995BETHESDA, Md--The lifetime risk of developing cancer for the US population is 44.8% for men and 39.3% for women, according to an analysis of incidence rates from the National Cancer Institute's SEER (Surveillance Epidemiology and End Results) program for 1973 to 1991.
ASTRO Names Richard Hoppe President-Elect
December 1st 1995MIAMI BEACH--Richard Hoppe, MD, has been named president-elect of the American Society for Therapeutic Radiology and Oncology (ASTRO). Dr. Hoppe is chairman of the Department of Radiation Oncology at Stanford University School of Medicine. He will take office at the Society's annual meeting to be held in Los Angeles next October.
Physicians Take Oath in Ruins Where Hippocrates Trained
December 1st 1995On the Greek island of Kos in the southeast Aegean, there is a cypress covered hill where ancient springs flow and herbs grow in abundance. People searching for good health have been coming to this hill for 25 generations. Hippocrates was born on Kos, and the hill holds the ruins of the ancient healing place, the Asclepieion.
1 Million Americans a Day Risk Injury in Tanning Salons
December 1st 1995BUENOS AIRES--The tanning salon industry has grown enormously in recent years, with as many as 2 million regular patrons in the United States, and 1 million people visiting daily, W. L. Morrison, MD, of Johns Hopkins University, said at the Sixth World Congress on Cancers of the Skin.
Pretreatment Levels of Hemoglobin May Predict Outcomes of Larynx Cancer Patients
December 1st 1995MIAMI BEACH--Pretreatment hemoglobin level has been shown to have an independent effect on local control and survival in patients with T1-T2 squamous cell carcinomas of the glottic larynx, Douglas A. Fein, MD, reported at the annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO). Based on this finding, it may be advisable to correct anemia in these patients before starting radiation therapy, he said.
Total Outpatient Program Cuts Transplant Cost
November 1st 1995LUXEMBOURG-In an effort to beat the skyrocketing costs of high-dose chemotherapy and transplantation, physicians at the Scripps Clinic, La Jolla, Calif, have launched a total outpatient therapy program that attempts to eliminate expensive hospital admissions.
DNA Repair Enzyme Decreases Skin Cancer Incidence in Animals
November 1st 1995BUENOS AIRES-Ultraviolet (UV) radiation contributes to skin cancer induction not only by transforming normal cells to cancer cells but also by impairing the host immune response to skin cancer, said Daniel Yarosh, PhD, president of Applied Genetics, Inc., Freeport, NY.
Notion of 'Global' Microbial Resistance May Be Oversimplified
November 1st 1995MONTREAL-The rising worldwide incidence of microbial resistance stems from a wide variety of causes and does not reflect a single global trend or etiology, Prof. Dr. Bernd Wiedemann, University of Bonn, Germany, said at a plenary session of the 19th International Congress of Chemotherapy.
Outpatient Oral Antibiotics Safe, Effective
November 1st 1995LUXEMBOURG-Outpatient oral antibiotic therapy can be as effective and safe as outpatient parenteral therapy in the treatment of febrile neutropenia, according to the latest trial results from M.D. Anderson Cancer Center's Ambulatory and Supportive Care Oncology Research Program (ASCORP).
Despite New Therapies, Malignant Pleural Mesothelioma Outcomes Are Not Improved
November 1st 1995BUFFALO, NY-While a combination of pleurectomy and intracavitary photodynamic therapy marginally improves survival rates for some patients with malignant pleural mesothelioma, "there exists no compelling evidence that treatment of any kind is superior to no treatment," reported Hiroshi Takita, MD, DSc, chief of the Department of Thoracic Surgery, Roswell Park Cancer Institute.
Use of Clarithromycin Prophylaxis Reduces MAC Infection, Mortality in Advanced AIDS Patients
November 1st 1995SAN FRANCISCO-Clarithromy-cin (Biaxin), a newer generation macro-lide, has been shown to have a definite favorable effect on survival when given prophylactically to patients with advanced AIDS, Mark Pierce, MD, reported at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy.
Low-Dose Acyclovir Recommended for HSV Prophylaxis in Leukemic Patients
November 1st 1995SAN FRANCISCO-Low-dose intravenous acyclovir (Zovirax) provides effective prophylaxis against Herpes simplex virus (HSV) infection or reactivation in leukemic patients undergoing intensive chemotherapy, Carole Miller, MD, said at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
Study Shows Outpatient Chemotherapy Less Expensive Than Home Health Care Delivery
November 1st 1995MARINA DEL REY, Calif-A detailed financial analysis of the costs associated with chemotherapy delivery showed home health care costs to be, on average, 2.5 times higher than those incurred in an outpatient clinic setting, said Patrick A. Grusenmeyer, MPA, financial administrator for the Ochsner Cancer Institute, New Orleans.
Extended Triple Antiretroviral Therapy Maintains Superiority
November 1st 1995SAN FRANCISCO-Two separate clinical trials have demonstrated that triple combination antiretroviral therapy maintains its superiority over double therapy in the extended treatment of HIV infection, although neither study included clinical morbidity as an endpoint.